Cargando…

Does remifentanil attenuate renal ischemia–reperfusion injury better than dexmedetomidine in rat kidney?

BACKGROUND: Ischemia–reperfusion (I/R) injury is a common cause of patient morbidity and mortality in the perioperative period. Patients undergoing long-lasting, abdominal, and urogenital surgeries with risk factors such as advanced age, peripheral artery disease, diabetes mellitus, renovascular dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Erkılıç, E, Kesimci, E, Alaybeyoğlu, F, Kılınç, I, Tural, R, Yazgan, A, Gümüş, T, Sepici Dinçel, A, Dumlu, EG, Kanbak, O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352155/
https://www.ncbi.nlm.nih.gov/pubmed/28331287
http://dx.doi.org/10.2147/DDDT.S126701
_version_ 1782514897832116224
author Erkılıç, E
Kesimci, E
Alaybeyoğlu, F
Kılınç, I
Tural, R
Yazgan, A
Gümüş, T
Sepici Dinçel, A
Dumlu, EG
Kanbak, O
author_facet Erkılıç, E
Kesimci, E
Alaybeyoğlu, F
Kılınç, I
Tural, R
Yazgan, A
Gümüş, T
Sepici Dinçel, A
Dumlu, EG
Kanbak, O
author_sort Erkılıç, E
collection PubMed
description BACKGROUND: Ischemia–reperfusion (I/R) injury is a common cause of patient morbidity and mortality in the perioperative period. Patients undergoing long-lasting, abdominal, and urogenital surgeries with risk factors such as advanced age, peripheral artery disease, diabetes mellitus, renovascular disease, and congestive heart failure are candidates for acute kidney injury (AKI) due to impaired renal perfusion and decreased functional renal reserve. Pharmacological agents with multiple functions and anti-oxidative and anti-inflammation properties may be promising preventative strategies for AKI. Recently, dexmedetomidine (dex) has been postulated to have renoprotective effects. OBJECTIVES: We aimed to investigate the protective effects of an intravenous anesthetic remifentanil in renal I/R injury in the rat in comparison with dex. MATERIALS AND METHODS: A total of 30 Sprague Dawley adult rats were randomly assigned into five groups: the control group (group C, n=6), the sham group (group Sh, n=6, saline-infused rats without I/R injury), the saline group (group S, n=6, saline-infused rats with I/R injury), the remifentanil-treated group (group REM, n=6), and the dexmedetomidine-treated group (group DEX, n=6). The infusions (saline, remifentanil, and dex) were started after anesthesia induction and right nephrectomy and continued until the end of the surgical procedure. In I/R injury groups, the left renal artery and vein were occluded together by a clamp for 30 minutes and reperfusion lasted for 30 minutes. The rats were sacrificed after reperfusion, and the left kidney tissue was harvested. Blood samples were drawn from all animals to evaluate plasma neutrophil gelatinase-associated lipocalin (NGAL) at the beginning, 15 minutes after ischemia, 15 minutes after reperfusion, and 6 hours after the surgical procedure (T0, T1, T2, and T3, respectively). RESULTS: The plasma NGAL levels exhibited increase at T1, T2, and T3 compared to the levels at T0 in group S (P<0.05). In group REM, there was a significant increase in plasma NGAL levels at T3 in comparison to those at T0, T1, and T2. The plasma NGAL levels at T2 in group S were significantly higher than those at T2 in group DEX (P<0.05). The groups S and REM showed significantly higher plasma NGAL levels at T3 compared to those at T0 (P<0.05). Upon histological examination, there was no difference among the study groups when left kidneys were evaluated (P>0.05). CONCLUSION: The NGAL levels and histopathological findings reflected protection by dex against renal I/R injury. However, the same exact results could not be mentioned for remifentanil depending on our study results.
format Online
Article
Text
id pubmed-5352155
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-53521552017-03-22 Does remifentanil attenuate renal ischemia–reperfusion injury better than dexmedetomidine in rat kidney? Erkılıç, E Kesimci, E Alaybeyoğlu, F Kılınç, I Tural, R Yazgan, A Gümüş, T Sepici Dinçel, A Dumlu, EG Kanbak, O Drug Des Devel Ther Original Research BACKGROUND: Ischemia–reperfusion (I/R) injury is a common cause of patient morbidity and mortality in the perioperative period. Patients undergoing long-lasting, abdominal, and urogenital surgeries with risk factors such as advanced age, peripheral artery disease, diabetes mellitus, renovascular disease, and congestive heart failure are candidates for acute kidney injury (AKI) due to impaired renal perfusion and decreased functional renal reserve. Pharmacological agents with multiple functions and anti-oxidative and anti-inflammation properties may be promising preventative strategies for AKI. Recently, dexmedetomidine (dex) has been postulated to have renoprotective effects. OBJECTIVES: We aimed to investigate the protective effects of an intravenous anesthetic remifentanil in renal I/R injury in the rat in comparison with dex. MATERIALS AND METHODS: A total of 30 Sprague Dawley adult rats were randomly assigned into five groups: the control group (group C, n=6), the sham group (group Sh, n=6, saline-infused rats without I/R injury), the saline group (group S, n=6, saline-infused rats with I/R injury), the remifentanil-treated group (group REM, n=6), and the dexmedetomidine-treated group (group DEX, n=6). The infusions (saline, remifentanil, and dex) were started after anesthesia induction and right nephrectomy and continued until the end of the surgical procedure. In I/R injury groups, the left renal artery and vein were occluded together by a clamp for 30 minutes and reperfusion lasted for 30 minutes. The rats were sacrificed after reperfusion, and the left kidney tissue was harvested. Blood samples were drawn from all animals to evaluate plasma neutrophil gelatinase-associated lipocalin (NGAL) at the beginning, 15 minutes after ischemia, 15 minutes after reperfusion, and 6 hours after the surgical procedure (T0, T1, T2, and T3, respectively). RESULTS: The plasma NGAL levels exhibited increase at T1, T2, and T3 compared to the levels at T0 in group S (P<0.05). In group REM, there was a significant increase in plasma NGAL levels at T3 in comparison to those at T0, T1, and T2. The plasma NGAL levels at T2 in group S were significantly higher than those at T2 in group DEX (P<0.05). The groups S and REM showed significantly higher plasma NGAL levels at T3 compared to those at T0 (P<0.05). Upon histological examination, there was no difference among the study groups when left kidneys were evaluated (P>0.05). CONCLUSION: The NGAL levels and histopathological findings reflected protection by dex against renal I/R injury. However, the same exact results could not be mentioned for remifentanil depending on our study results. Dove Medical Press 2017-03-08 /pmc/articles/PMC5352155/ /pubmed/28331287 http://dx.doi.org/10.2147/DDDT.S126701 Text en © 2017 Erkılıç et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Erkılıç, E
Kesimci, E
Alaybeyoğlu, F
Kılınç, I
Tural, R
Yazgan, A
Gümüş, T
Sepici Dinçel, A
Dumlu, EG
Kanbak, O
Does remifentanil attenuate renal ischemia–reperfusion injury better than dexmedetomidine in rat kidney?
title Does remifentanil attenuate renal ischemia–reperfusion injury better than dexmedetomidine in rat kidney?
title_full Does remifentanil attenuate renal ischemia–reperfusion injury better than dexmedetomidine in rat kidney?
title_fullStr Does remifentanil attenuate renal ischemia–reperfusion injury better than dexmedetomidine in rat kidney?
title_full_unstemmed Does remifentanil attenuate renal ischemia–reperfusion injury better than dexmedetomidine in rat kidney?
title_short Does remifentanil attenuate renal ischemia–reperfusion injury better than dexmedetomidine in rat kidney?
title_sort does remifentanil attenuate renal ischemia–reperfusion injury better than dexmedetomidine in rat kidney?
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352155/
https://www.ncbi.nlm.nih.gov/pubmed/28331287
http://dx.doi.org/10.2147/DDDT.S126701
work_keys_str_mv AT erkılıce doesremifentanilattenuaterenalischemiareperfusioninjurybetterthandexmedetomidineinratkidney
AT kesimcie doesremifentanilattenuaterenalischemiareperfusioninjurybetterthandexmedetomidineinratkidney
AT alaybeyogluf doesremifentanilattenuaterenalischemiareperfusioninjurybetterthandexmedetomidineinratkidney
AT kılınci doesremifentanilattenuaterenalischemiareperfusioninjurybetterthandexmedetomidineinratkidney
AT turalr doesremifentanilattenuaterenalischemiareperfusioninjurybetterthandexmedetomidineinratkidney
AT yazgana doesremifentanilattenuaterenalischemiareperfusioninjurybetterthandexmedetomidineinratkidney
AT gumust doesremifentanilattenuaterenalischemiareperfusioninjurybetterthandexmedetomidineinratkidney
AT sepicidincela doesremifentanilattenuaterenalischemiareperfusioninjurybetterthandexmedetomidineinratkidney
AT dumlueg doesremifentanilattenuaterenalischemiareperfusioninjurybetterthandexmedetomidineinratkidney
AT kanbako doesremifentanilattenuaterenalischemiareperfusioninjurybetterthandexmedetomidineinratkidney